Kezar Life Sciences Q2 2024 Adj EPS $(0.30) Beats $(0.32) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kezar Life Sciences (NASDAQ:KZR) reported a Q2 2024 adjusted EPS of $(0.30), beating the analyst consensus estimate of $(0.32) by 6.25%.
August 13, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kezar Life Sciences reported a Q2 2024 adjusted EPS of $(0.30), which is better than the analyst estimate of $(0.32). This positive earnings surprise could boost investor confidence in the short term.
The better-than-expected EPS indicates that the company is performing slightly better than analysts anticipated, which is likely to have a positive short-term impact on the stock price as it boosts investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100